Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study-Reference-Cited by-同舟云学术

Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study

Published:2019-08 Issue:9 Volume:17 Page:1788-1798.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Targownik Laura E.,Benchimol Eric I.,Bernstein Charles N.,Singh Harminder,Lix Lisa,Tennakoon Aruni,Leung Stella,Aviña Antonio,Coward Stephanie,Jones Jennifer,Kaplan Gil,Murthy Sanjay K.,Nguyen Geoffrey C.,Peña-Sánchez Juan Nicolás

Funder

Crohn's and Colitis Canada

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference15 articles.

1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group;Targan;N Engl J Med,1997

2. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease;Rutgeerts;Gastroenterology,1999

3. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

4. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis;Panaccione;Gastroenterology,2014

5. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease;Feagan;Gastroenterology,2014

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review);Koloproktologia;2024-06-21

2. Characterization of Biologic Discontinuation Among Pediatric Patients with Crohn’s Disease;Clinical Gastroenterology and Hepatology;2024-05

3. Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis;Clinical Gastroenterology and Hepatology;2024-01

4. Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?;Digestive and Liver Disease;2023-12

5. Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab;Digestive and Liver Disease;2023-11